NasdaqGS - Delayed Quote • USD
C4 Therapeutics, Inc. (CCCC)
At close: April 24 at 4:00 PM EDT
Pre-Market: 9:07 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 9 | 8 |
| Avg. Estimate | -0.35 | -0.5 | -1.85 | -1.92 |
| Low Estimate | -0.6 | -0.73 | -2.52 | -3.01 |
| High Estimate | -0.18 | -0.28 | -1.08 | -0.81 |
| Year Ago EPS | -0.71 | -0.73 | -2.65 | -1.85 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 6 | 6 | 6 |
| Avg. Estimate | 8.1M | 3.88M | 26.83M | 21.45M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 12.5M | 8.5M | 46M | 50M |
| Year Ago Sales | 5.15M | 2.66M | 20.76M | 26.83M |
| Sales Growth (year/est) | 57.30% | 45.60% | 29.30% | -20.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.75 | -0.69 | -0.66 | -0.68 |
| EPS Actual | -0.71 | -0.73 | -0.55 | -0.7 |
| Difference | 0.04 | -0.04 | 0.11 | -0.02 |
| Surprise % | 5.30% | -5.80% | 16.70% | -2.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.35 | -0.5 | -1.85 | -1.92 |
| 7 Days Ago | -0.35 | -0.5 | -1.85 | -1.92 |
| 30 Days Ago | -0.35 | -0.5 | -1.85 | -1.92 |
| 60 Days Ago | -0.38 | -0.54 | -2.23 | -2.67 |
| 90 Days Ago | -0.53 | -0.56 | -2.27 | -2.66 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CCCC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 50.70% | -- | -- | 1.50% |
| Next Qtr. | 31.50% | -- | -- | 11.40% |
| Current Year | 30.20% | -- | -- | 5.20% |
| Next Year | -3.80% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 22.30% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 2/26/2024 |
| Reiterates | Stifel: Buy to Buy | 2/23/2024 |
| Upgrade | JP Morgan: Underweight to Neutral | 1/29/2024 |
| Upgrade | Stifel: Hold to Buy | 12/13/2023 |
| Upgrade | Morgan Stanley: Underweight to Equal-Weight | 11/6/2023 |
| Maintains | BMO Capital: Outperform to Outperform | 11/3/2023 |
Related Tickers
ARQT Arcutis Biotherapeutics, Inc.
8.75
+0.11%
STTK Shattuck Labs, Inc.
9.90
+4.32%
ARVN Arvinas, Inc.
32.54
-4.29%
VTYX Ventyx Biosciences, Inc.
4.2400
-2.53%
ANVS Annovis Bio, Inc.
12.74
+7.24%
ALT Altimmune, Inc.
7.08
-6.47%
XLO Xilio Therapeutics, Inc.
1.0600
+0.95%
OCEA Ocean Biomedical, Inc.
1.4150
-4.39%
CADL Candel Therapeutics, Inc.
6.05
+2.37%
GLUE Monte Rosa Therapeutics, Inc.
5.47
-1.26%